1. Resection of liver metastases in patients with gastrointestinal stromal tumors in the imatinib era: A nationwide retrospective study
- Author
-
M.F.J. Seesing, R. Tielen, R. van Hillegersberg, F. van Coevorden, K.P. de Jong, I.D. Nagtegaal, C. Verhoef, J.H.W. de Wilt, H.H. Hartgrink, C. Sietses, G. Kazemier, T.M. van Gulik, M.H.A. Bemelmans, G.A. Patijn, K. Bosscha, B. van Ramshorst, J.R.M. van der Sijp, R. Roumen, Surgery, Groningen Institute for Organ Transplantation (GIOT), and Guided Treatment in Optimal Selected Cancer Patients (GUTS)
- Subjects
Male ,Multivariate analysis ,Kaplan-Meier Estimate ,THERAPY ,Gastroenterology ,Tyrosine-kinase inhibitor ,Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14] ,PROGNOSTIC-FACTORS ,0302 clinical medicine ,RESIDUAL DISEASE ,Tumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14] ,Liver metastasis ,Gastrointestinal Neoplasms ,Netherlands ,Aged, 80 and over ,Liver resection ,GiST ,Liver Neoplasms ,General Medicine ,Middle Aged ,Survival Rate ,Oncology ,030220 oncology & carcinogenesis ,SURGICAL-MANAGEMENT ,Imatinib Mesylate ,030211 gastroenterology & hepatology ,Female ,GIST ,medicine.drug ,Adult ,medicine.medical_specialty ,medicine.drug_class ,Gastrointestinal Stromal Tumors ,HEPATIC RESECTION ,MESYLATE ,Antineoplastic Agents ,Disease-Free Survival ,03 medical and health sciences ,Internal medicine ,medicine ,Hepatectomy ,Humans ,Survival analysis ,Aged ,Proportional Hazards Models ,Retrospective Studies ,Gastrointestinal stromal cancer ,business.industry ,Metastasectomy ,Retrospective cohort study ,Imatinib ,TYROSINE-KINASE ,Surgery ,C-KIT ,Clinical trial ,Cytopathology ,business - Abstract
Contains fulltext : 171401.pdf (Publisher’s version ) (Closed access) INTRODUCTION: Liver metastases are common in patients with gastrointestinal stromal tumors (GIST). In the absence of randomized controlled clinical trials, the effectiveness of surgery as a treatment modality is unclear. This study identifies safety and outcome in a nationwide study of all patients who underwent resection of liver metastases from GIST. METHODS: Patients were included using the national registry of histo- and cytopathology (PALGA) of the Netherlands from 1999. Kaplan Meier survival analysis was used for calculating survival outcome. Univariate and multivariate regression analyses were carried out for the assessment of potential prognostic factors. RESULTS: A total of 48 patients (29 male, 19 female) with a median age of 58 (range 28-81) years were identified. Preoperative and postoperative tyrosine kinase inhibitor therapy was given to 30 (63%) and 36 (75%) patients, respectively. A minor liver resection was performed in 32 patients, 16 patients underwent major liver resection. Median follow-up was 27 (range 1-146) months. Median progression-free survival (PFS) was 28 (range 1-121) months. One-, three-, and five-year PFS was 93%, 67%, and 59% respectively. Median overall survival (OS) was 90 (range 1-146) months from surgery. The one-, three-, and five-year OS was 93%, 80%, and 76% respectively. R0 resection was the only independent significant prognostic factor for DFS and OS at multivariate analysis. CONCLUSION: Resection of liver metastases in GIST patients combined with imatinib may be associated with prolonged overall survival when a complete resection is achieved.
- Published
- 2016